JP2011517662A5 - - Google Patents

Download PDF

Info

Publication number
JP2011517662A5
JP2011517662A5 JP2010549807A JP2010549807A JP2011517662A5 JP 2011517662 A5 JP2011517662 A5 JP 2011517662A5 JP 2010549807 A JP2010549807 A JP 2010549807A JP 2010549807 A JP2010549807 A JP 2010549807A JP 2011517662 A5 JP2011517662 A5 JP 2011517662A5
Authority
JP
Japan
Prior art keywords
mmp
binding protein
antibody
binding
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010549807A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011517662A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/035840 external-priority patent/WO2009111450A2/en
Publication of JP2011517662A publication Critical patent/JP2011517662A/ja
Publication of JP2011517662A5 publication Critical patent/JP2011517662A5/ja
Withdrawn legal-status Critical Current

Links

JP2010549807A 2008-03-03 2009-03-03 メタロプロテアーゼ９結合タンパク質 Withdrawn JP2011517662A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US3307508P 2008-03-03 2008-03-03
US61/033,075 2008-03-03
US5493808P 2008-05-21 2008-05-21
US61/054,938 2008-05-21
US13829708P 2008-12-17 2008-12-17
US61/138,297 2008-12-17
PCT/US2009/035840 WO2009111450A2 (en) 2008-03-03 2009-03-03 Metalloproteinase 9 binding proteins

Publications (2)

Publication Number Publication Date
JP2011517662A JP2011517662A (ja) 2011-06-16
JP2011517662A5 true JP2011517662A5 (https=) 2012-04-19

Family

ID=41056597

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010549807A Withdrawn JP2011517662A (ja) 2008-03-03 2009-03-03 メタロプロテアーゼ９結合タンパク質

Country Status (6)

Country Link
US (2) US8008445B2 (https=)
EP (1) EP2262529A4 (https=)
JP (1) JP2011517662A (https=)
AU (1) AU2009222048A1 (https=)
CA (1) CA2717576A1 (https=)
WO (1) WO2009111450A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2524015T3 (es) 2005-12-30 2014-12-03 Dyax Corporation Proteínas de enlazamiento a la metaloproteinasa
WO2009079585A2 (en) 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins
WO2009079581A1 (en) * 2007-12-17 2009-06-25 Dyax Corp. Evaluating mmp expression in patient stratification and other therapeutic, diagnostic and prognostic methods for cancer
AU2009221916A1 (en) 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
JP2011517662A (ja) 2008-03-03 2011-06-16 ダイアックス コーポレーション メタロプロテアーゼ９結合タンパク質
US20110135573A1 (en) * 2009-09-03 2011-06-09 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
US20130012451A1 (en) * 2009-12-21 2013-01-10 The Research Foundation Of State University Of New York Compositions and methods for inhibiting mmp-9-mediated cell migration
EP2523600A4 (en) * 2010-01-12 2015-07-15 Univ Ben Gurion TARGETED RELEASE SYSTEMS FOR DIAGNOSTIC APPLICATIONS
CA2787311C (en) 2010-01-27 2017-08-15 Yeda Research And Development Co. Ltd. Antibodies that inhibit metalloproteins
CA2792163A1 (en) * 2010-03-05 2011-09-09 The Curators Of The University Of Missouri Biomarkers of osteoarthritis
WO2011133555A2 (en) 2010-04-20 2011-10-27 The Research Foundation Of State University Of New York Compositions and methods for inhibiting matrix metalloproteinase (mmp)-mediated cell migration
JP2013536438A (ja) * 2010-08-23 2013-09-19 ジ・オハイオ・ステート・ユニバーシティ・リサーチ・ファンデーション 急性炎症を含めた状態に関する診断試験としてのハプトグロビン−マトリックスメタロプロテイナーゼ９複合体に関するｅｌｉｓａ
CN108387744A (zh) 2010-08-26 2018-08-10 弗·哈夫曼-拉罗切有限公司 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途
EP2608809B1 (en) 2010-08-27 2019-05-22 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
AU2015201367B2 (en) * 2010-08-27 2016-12-15 Gilead Sciences, Inc. Antibodies to matrix metalloproteinase 9
WO2013059439A2 (en) 2011-10-21 2013-04-25 Dyax Corp. Combination therapy comprising an mmp-14 binding protein
WO2013130078A1 (en) * 2012-02-29 2013-09-06 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
HK1204926A1 (en) 2012-02-29 2015-12-11 吉联亚生物科技有限公司 Antibodies to matrix metalloproteinase 9
ES2702315T3 (es) 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
EP3782604A1 (en) 2013-07-31 2021-02-24 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
KR20150029457A (ko) * 2013-09-10 2015-03-18 삼성전자주식회사 아넥신 a1에 결합하는 폴리펩타이드 및 그의 용도
FR3015986A1 (fr) * 2013-12-30 2015-07-03 Lvmh Rech Aptameres inhibiteurs de l'activite enzymatique de la proteine mmp-9
EP3110847A1 (en) * 2014-02-27 2017-01-04 Gilead Sciences, Inc. Antibodies to matrix metalloproteinase 9 and methods of use thereof
EP2985296A1 (en) * 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
EP2985295A1 (en) * 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
BR112018006251A2 (pt) 2015-09-30 2018-10-16 Janssen Biotech Inc anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso
JP2016106147A (ja) * 2016-03-14 2016-06-16 ギリアード バイオロジックス， インコーポレイテッド マトリックスメタロプロテイナーゼ９に対する抗体
US20200306283A1 (en) 2016-06-22 2020-10-01 William Warren HARLESS Cancer treatment and metastasis inhibition using an anti-cancer stem cell agent in combination with a neu1 sialidase inhibitor or a cytokine inhibitor after primary cancer treatment
TWI767915B (zh) 2016-06-27 2022-06-21 加州大學董事會 Ror-1與btk拮抗劑的組合
EP3565598A4 (en) 2017-01-03 2020-10-28 Trellis Bioscience, LLC NATIVE HUMAN ANTIBODIES FOR TIM-3 AND B7-H3 IMMUNE CHECKPOINT MODULATION TARGETS
WO2020237092A2 (en) * 2019-05-21 2020-11-26 The Regents Of The University Of California Mmp-9 antibodies and methods of use thereof
WO2022170126A2 (en) * 2021-02-05 2022-08-11 Adagio Therapeutics, Inc. Compounds specific to coronavirus s protein and uses thereof
JP7474736B2 (ja) * 2021-12-27 2024-04-25 花王株式会社 白斑の予防又は改善剤の評価又は選択方法
CN120230208A (zh) * 2024-08-07 2025-07-01 上海交通大学医学院附属第九人民医院 一组sh23同源簇全人源tsh受体阻断性单克隆抗体及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0736302A3 (en) * 1995-03-23 1997-06-04 Stichting Rega V Z W Protease inhibitors, DNA construction for protease expression and a method for measuring proteases and / or protease inhibitors
GB9809764D0 (en) 1998-05-07 1998-07-08 Isis Innovation MMP-9 Gene polymorphisms
US7101975B1 (en) * 1999-07-13 2006-09-05 University Of Southern California Method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and β1 integrins
CA2379373A1 (en) * 1999-07-13 2001-01-18 University Of Southern California Novel method and composition for inhibition of angiogenesis using antagonists based on mmp-9 and .beta.1 integrins
WO2001026671A1 (en) 1999-10-12 2001-04-19 Smithkline Beecham Corporation Methods of treatment using dual matrix-metalloproteinase-2 and matrix metalloproteinase-9 inhibitors
US6573096B1 (en) * 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
AU2001274894A1 (en) * 2000-05-22 2001-12-03 Pharmacia And Upjohn Company Novel matrix metalloproteinases
AR028606A1 (es) 2000-05-24 2003-05-14 Smithkline Beecham Corp Nuevos inhibidores de mmp-2/mmp-9
KR100919593B1 (ko) 2000-06-29 2009-09-29 아보트 러보러터리즈 이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물
WO2002026829A1 (en) * 2000-09-25 2002-04-04 Rega Stichting Vzw Method for the production of human antibodies, antibodies thus obtained and their use in therapy and diagnosis
US20070258987A1 (en) * 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
WO2002066057A2 (en) * 2001-02-23 2002-08-29 Biophage Inc. Methods and compositions for preventing and treating neutrophil-mediated diseases
EP1322957B1 (en) * 2001-05-04 2009-08-12 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
WO2003044058A2 (en) * 2001-11-23 2003-05-30 Universite Catholique De Louvain Medical use of antibodies directed against human matrix metalloproteinases or related tissue proteinases for the treatment of abnormal uterine bleeding and endometriosis
WO2004037286A2 (en) 2002-10-23 2004-05-06 F. Hoffmann-La Roche Ag Combination of a trioxopyrimidine compound inhibitor and an anti-tumor agent, and uses thereof
ATE517926T1 (de) 2003-04-04 2011-08-15 Yeda Res & Dev Antikörper zur hemmung der aktivität von mmp-2 und mmp-9
US7435800B2 (en) * 2003-05-23 2008-10-14 Chi-Mei Medical Center Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation
US20050118632A1 (en) * 2003-11-06 2005-06-02 Jian Chen Polynucleotides and polypeptides encoding a novel metalloprotease, Protease-40b
US20060002969A1 (en) * 2004-01-27 2006-01-05 University Of Washington Methods for reducing the foreign body reaction
FI20040572A0 (fi) * 2004-04-23 2004-04-23 Ctt Cancer Targeting Tech Oy Matriisi-metalloproteinaasin aktiviteetin inhibiittorit
CN100497324C (zh) 2004-05-27 2009-06-10 武汉科艾硒医药科技发展有限公司 具有抗纤维化及抑制明胶酶活性的化合物及其应用
US20090209615A1 (en) 2004-09-27 2009-08-20 Stuart Lipton Inhibitors of matrix metalloproteinases to treat neurological disorders
WO2006084109A2 (en) 2005-02-02 2006-08-10 Pro Term, Inc. Salivary protease assays for identifying increased risk of preterm delivery induced by premature rupture of fetal membranes
DE102005015040A1 (de) 2005-03-31 2006-10-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
US20070203209A1 (en) * 2005-08-18 2007-08-30 Wilmin Bartolini Useful indole compounds
US8092819B2 (en) * 2006-01-27 2012-01-10 Cook Medical Technologies LLC. Implantable medical device coated with a bioactive agent
WO2007149948A2 (en) 2006-06-20 2007-12-27 The Gov. Of The Usa As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for diagnosis and treatment of tumors
KR20100071972A (ko) * 2007-08-15 2010-06-29 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Ｍｍｐ-9의 조절인자 및 그의 용도
KR20090034637A (ko) 2007-10-04 2009-04-08 엘지전자 주식회사 차량용 거치대
WO2009079585A2 (en) 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins
WO2009079581A1 (en) 2007-12-17 2009-06-25 Dyax Corp. Evaluating mmp expression in patient stratification and other therapeutic, diagnostic and prognostic methods for cancer
AU2009221916A1 (en) * 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
JP2011517662A (ja) 2008-03-03 2011-06-16 ダイアックス コーポレーション メタロプロテアーゼ９結合タンパク質
WO2010045388A2 (en) 2008-10-14 2010-04-22 Dyax Corp. Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
JP2013533206A (ja) 2008-10-22 2013-08-22 ダイアクス コーポレーション 炎症性障害のための、プロテアーゼ結合タンパク質を含む併用療法
US20110135573A1 (en) 2009-09-03 2011-06-09 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins

Similar Documents

Publication Publication Date Title
US8013125B2 (en) Metalloproteinase 9 and metalloproteinase 2 binding proteins
US8008445B2 (en) Metalloproteinase 9 binding proteins
JP2011517662A5 (https=)
JP2011517320A5 (https=)
US8114968B2 (en) Metalloproteinase-12 specific monoclonal antibody
US20110135573A1 (en) Metalloproteinase 9 and metalloproteinase 2 binding proteins
US12350347B2 (en) Nucleic acids encoding anti-IL1RAP antibodies and their uses
AU2011204349C1 (en) Plasma kallikrein binding proteins
CN110078827A (zh) 结合表皮生长因子受体的可活化的抗体其使用方法
US11981732B2 (en) Anti-TMEFF1 antibodies and antibody drug conjugates
WO2009097397A2 (en) Metalloproteinase binding proteins
WO2010045388A2 (en) Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
AU2019204295A1 (en) Plasma kallikrein binding proteins